Differential Impact of Cysteine Cathepsins on Genetic Mouse Models of De novo Carcinogenesis: Cathepsin B as Emerging Therapeutic Target.
about
Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probesCharacterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage PolarizationLysosomal protein turnover contributes to the acquisition of TGFβ-1 induced invasive properties of mammary cancer cells.Activity of Proteolytic Enzymes and Level of Cystatin C in the Peripartum PeriodlncRNA recruits RNAi and the exosome to dynamically regulate pho1 expression in response to phosphate levels in fission yeast.Metastasis review: from bench to bedside.Impact of proteolytic enzymes in colorectal cancer development and progression.Deficiency of filaggrin regulates endogenous cysteine protease activity, leading to impaired skin barrier function.Cathepsin B as a potential cystatin M/E target in the mouse hair follicle.Cathepsin B-deficient mice as source of monoclonal anti-cathepsin B antibodiesProteases and cytokines as mediators of interactions between cancer and stromal cells in tumours.Synthesis and radiopharmacological characterisation of a fluorine-18-labelled azadipeptide nitrile as a potential PET tracer for in vivo imaging of cysteine cathepsins.Rapid label-free profiling of oral cancer biomarker proteins using nano-UPLC-Q-TOF ion mobility mass spectrometry.MMP1, MMP9, and COX2 expressions in promonocytes are induced by breast cancer cells and correlate with collagen degradation, transformation-like morphological changes in MCF-10A acini, and tumor aggressiveness.High Resolution Proteomic Analysis of the Cervical Cancer Cell Lines Secretome Documents Deregulation of Multiple Proteases.Combinatorial omics analysis reveals perturbed lysosomal homeostasis in collagen VII-deficient keratinocytes.A lysosome-targeted drug delivery system based on sorbitol backbone towards efficient cancer therapy.Design, characterization and cellular uptake studies of fluorescence-labeled prototypic cathepsin inhibitors.
P2860
Q26827307-D111AD7B-3CE7-4648-8BB5-7115E06DAC82Q28552410-9343EBE0-6D3E-4F02-B6D9-8A97CC622F93Q35116175-196CFBAA-4404-4EAD-8804-D3C2082AF256Q36556164-6204F934-D749-4B67-ACB6-00183F781212Q37582980-4B145BCE-CADC-41F5-97C0-74CE107DDFBBQ38237985-D112FF44-CF39-4BF3-B504-AFD981B2794FQ38259533-940D8E67-635B-4697-93C8-99D2C907C33AQ38701894-5941D149-4D09-4492-A70A-63B00F04B952Q38735425-A74833BD-7044-43D1-BAF0-5565F5CA448FQ38957889-A79F32F8-BFE0-4CF2-8AF0-F157B833AE12Q39046432-82DAD5C5-822B-4137-92C2-482262919DD6Q39137404-7A405039-2907-4210-AC84-2ED2B8124A81Q40193407-52AFE76E-90FD-4AA2-8AE1-D55ECCC14B02Q42182045-CE3821BC-3E86-4ADE-AA27-ADABE480ACDAQ45874046-63E1F4EC-FCFC-4D32-9970-604C10BC555BQ50078076-B7924683-74C2-40BB-8857-E07D9C006BB8Q53031862-341D95EF-5F28-48B8-A2F2-FD603FE6DADAQ53372260-082B9532-CB96-41A4-9679-F7B60BC4A713
P2860
Differential Impact of Cysteine Cathepsins on Genetic Mouse Models of De novo Carcinogenesis: Cathepsin B as Emerging Therapeutic Target.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Differential Impact of Cystein ...... s Emerging Therapeutic Target.
@ast
Differential Impact of Cystein ...... s Emerging Therapeutic Target.
@en
type
label
Differential Impact of Cystein ...... s Emerging Therapeutic Target.
@ast
Differential Impact of Cystein ...... s Emerging Therapeutic Target.
@en
prefLabel
Differential Impact of Cystein ...... s Emerging Therapeutic Target.
@ast
Differential Impact of Cystein ...... s Emerging Therapeutic Target.
@en
P2093
P2860
P356
P1476
Differential Impact of Cystein ...... as Emerging Therapeutic Target
@en
P2093
Achim Krüger
Christoph Peters
Olga Vasiljeva
P2860
P356
10.3389/FPHAR.2012.00133
P577
2012-07-11T00:00:00Z